Epizyme Inc.’s Phase I study, designed mainly to determine the safety of EPZ-5676, an inhibitor of the DOT1L histone methyltransferase (HMT) for the treatment of acute leukemia with rearrangements in the mixed lineage leukemia gene (MLL-r), ended up showing treatment effects in four of eight patients.